| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.42B | $28.19B | $26.32B | $25.98B | $25.42B | $23.36B | $23.75B | $22.85B |
| Cost of Revenue | $12.86B | $8.41B | $6.41B | $6.45B | $6.16B | $4.36B | $4.10B | $4.07B |
| Gross Profit | $20.57B | $19.77B | $19.92B | $19.52B | $19.27B | $19.01B | $19.65B | $18.78B |
| Gross Margin | 61.53% | 70.15% | 75.66% | 75.16% | 75.77% | 81.35% | 82.73% | 82.19% |
| Operating Expenses | $13.31B | $11.88B | $10.35B | $11.89B | $10.13B | $9.33B | $9.38B | $8.81B |
| Operating Income | $7.26B | $7.90B | $9.57B | $7.64B | $9.14B | $9.67B | $10.26B | $9.97B |
| Operating Margin | 21.71% | 28.01% | 36.34% | 29.40% | 35.95% | 41.41% | 43.22% | 43.65% |
| Net Income | $4.09B | $6.72B | $6.55B | $5.89B | $7.26B | $7.84B | $8.39B | $1.98B |
| Net Margin | 12.24% | 23.83% | 24.89% | 22.68% | 28.57% | 33.57% | 35.35% | 8.66% |
| EPS (Basic) | $7.62 | $12.56 | $12.18 | $10.34 | $12.40 | $12.96 | $12.70 | $2.71 |
| EBITDA | $13.36B | $14.80B | $12.17B | $11.30B | $13.00B | $12.63B | $12.88B | $12.86B |
| Stock Option Compensation Expense | $530.00M | $431.00M | $401.00M | $341.00M | $330.00M | $308.00M | $311.00M | $329.00M |
| Price To Earnings Ratio | 34.48 | 22.94 | 21.57 | 21.76 | 18.55 | 18.60 | 15.33 | 64.23 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $141.01B | $154.09B | $141.30B | $128.23B | $134.73B | $145.85B | $128.68B | $127.12B |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $91.84B | $97.15B | $65.12B | $61.16B | $62.95B | $59.71B | $66.42B | $79.95B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $85.96B | $90.92B | $61.46B | $54.47B | $53.54B | $50.03B | $53.92B | $54.71B |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $5.88B | $6.23B | $3.66B | $6.70B | $9.41B | $9.67B | $12.50B | $25.24B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $5.88B | $6.23B | $3.66B | $6.70B | $9.41B | $9.67B | $12.50B | $25.24B |
| Total Liabilities & Stockholders Equity | $91.84B | $97.15B | $65.12B | $61.16B | $62.95B | $59.71B | $66.42B | $79.95B |
| Book Value Per Share | $10.86 | $11.65 | $6.80 | $11.75 | $16.06 | $15.99 | $18.91 | $34.53 |
| Tangible Book Value Per Share | $-74.79 | $-84.18 | $-51.95 | $-41.00 | $-37.32 | $-40.40 | $-14.59 | $2.56 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 4.45% | 6.91% | 10.06% | 9.63% | 11.54% | 13.13% | 12.64% | 2.48% |
| Return on Equity | 69.59% | 107.78% | 178.97% | 87.96% | 77.20% | 81.07% | 67.15% | 7.84% |
| Return on Invested Capital | 8.91% | 8.42% | 16.72% | 13.69% | 15.88% | 16.66% | 15.74% | 2.85% |
| Quick Ratio | 0.95 | 1.13 | 1.10 | 1.26 | 1.48 | 1.16 | 2.57 | 5.17 |
| Current Ratio | 1.26 | 1.65 | 1.41 | 1.59 | 1.81 | 1.44 | 2.79 | 5.49 |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $4.09B | $6.72B | $6.55B | $5.89B | $7.26B | $7.84B | $8.39B | $1.98B |
| Depreciation | $5.59B | $4.07B | $3.42B | $3.40B | $3.60B | $2.21B | $1.95B | $1.96B |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $11.49B | $8.47B | $9.72B | $9.26B | $10.50B | $9.15B | $11.30B | $11.18B |
| Capital Expenditures | $1.10B | $1.11B | $936.00M | $880.00M | $608.00M | $618.00M | $738.00M | $664.00M |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $4.83B | $4.56B | $4.20B | $4.01B | $3.75B | $3.51B | $3.51B | $3.37B |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $200.00M | $0.00 | $6.36B | $4.97B | $3.49B | $7.70B | $17.79B | $3.16B |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $10.39B | $7.36B | $8.79B | $8.38B | $9.89B | $8.53B | $10.56B | $10.51B |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Why it moved over time
Amgen reported Q2 results that beat revenue and EPS estimates, topped $10 billion in revenue, and raised full-year guidance, pointing to stronger-than-expected commercial momentum and an upgraded 2026 outlook.
Key fact: Q2 revenue exceeded $10 billion and Amgen raised full-year guidance by $1 billion and $0.50 per share.
seekingalpha.com: Amgen: First $10 Billion Quarter, More Growth AheadAmgen disclosed a cybersecurity breach in a regulatory filing saying hackers stole company and patient data from third-party cloud storage, a material incident that could prompt regulatory scrutiny, remediation costs and reputational risk.
Key fact: Regulatory filing said hackers stole company and patient health information from cloud storage systems run by third-party providers.
zacks.com: Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?Amgen disclosed a cybersecurity breach in a regulatory filing saying hackers stole company and patient health data, a material privacy and compliance issue that could trigger investigations, remediation costs and reputational risk.
Key fact: A July 31 regulatory filing said hackers stole company data and patient health information from third-party cloud storage systems.
zacks.com: Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?Amgen's July 31 disclosure that hackers stole company and patient health data is likely the catalyst, raising regulatory, remediation and reputational risks that could increase costs and affect product uptake.
Key fact: On July 31, Amgen said hackers stole company and patient health information from third-party cloud storage systems, per a regulatory filing.
defenseworld.net: Alpine Woods Capital Investors LLC Purchases 4,003 Shares of Amgen Inc. $AMGNShares rose after reports that Amgen's monthly weight‑loss drug MariTide has six Phase 3 trials underway, marking a late‑stage push into the competitive GLP‑1 market against Eli Lilly and Novo Nordisk.
Key fact: Amgen's MariTide monthly weight‑loss injection has six Phase 3 trials running.
The Motley Fool: Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients